@BegolLet’s hope you’re right. I’d like to see the price rebound...

@Begol

Let’s hope you’re right. I’d like to see the price rebound slowly but consistently post ex-entitlement this Wednesday and hope for no dump post rights issue. I can’t speak for whether the CR instos will dump at 30/40% upside as has been forecasted but we shall see. As @Uboy has suggested, the seemingly unnecessary delay of the P2B/P3 trial commencement until mid 2022 seems suspicious. We’ve always seen the emphasis on how serious DMD is and how willing regulators are to get treatments approved (FDA’s approval of Exondys-51 despite no clinical improvement shown). It seems strange that we’d see the European trials starting later than anticipated with seemingly no indication as to why. Let’s hope for some clarification soon (cautiously optimistic for dual EMA/FDA trial as Uboy/Wayne have suggested)